M6620 First in Human Study

Sponsor

EMD Serono Research & Development Institute, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT02157792

Collaborator

Merck KGaA, Darmstadt, Germany (Industry)

200

Enrollment

Locations

Arms

Actual Duration (Months)

6.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumor	Drug: M6620 Drug: Gemcitabine Drug: Cisplatin Drug: Etoposide Drug: Carboplatin Drug: Irinotecan	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

200 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Actual Study Start Date :

Dec 10, 2012

Actual Primary Completion Date :

Mar 11, 2020

Actual Study Completion Date :

Mar 11, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part A This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.	Drug: M6620 Other Names: VX-970 Drug: Gemcitabine Drug: Cisplatin
Experimental: Part B This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.	Drug: M6620 Other Names: VX-970 Drug: Cisplatin Drug: Etoposide
Experimental: Part B2 This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.	Drug: M6620 Other Names: VX-970 Drug: Irinotecan
Experimental: Part C1 This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.	Drug: M6620 Other Names: VX-970 Drug: Gemcitabine
Experimental: Part C2 This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.	Drug: M6620 Other Names: VX-970 Drug: Cisplatin
Experimental: Part C3 This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.	Drug: M6620 Other Names: VX-970 Drug: Cisplatin Drug: Carboplatin

Outcome Measures

Primary Outcome Measures

Parts A, B, B2, C1, C2, C3: Safety parameters, including adverse event (AEs), clinical laboratory values (serum chemistry, hematology, and urinalysis), vital signs, and electrocardiogram (ECG) assessments [Screening through Safety Follow-up (approximately 22 weeks)]
Parts C1, C2, C3: Overall Response Rate (ORR) for all participants in Part C1 (NSCLC), ORR for participants in Part C2 (TNBC) who are basaloid subtype and BRCA1/BRCA2 germline wild-type, ORR for all participants in Part C3 (SCLC) [1 year]

Secondary Outcome Measures

Part A: Maximum tolerated dose (MTD) of M6620 administered in combination with cisplatin and gemcitabine and in combination with gemcitabine [1 year]
Part A: Pharmacokinetic (PK) parameter estimates of M6620 in combination with cisplatin and gemcitabine and in combination with gemcitabine [1 year]
Part B, B2: Maximum tolerated dose (MTD) of M6620 in combination with cisplatin or cisplatin and etoposide or irinotecan [1 year]
Part B, B2: PK parameter estimates of M6620 in combination with cisplatin or cisplatin and etoposide or irinotecan [1 year]
Part B: PK parameter estimates of etoposide derived from plasma concentration-time data after coadministration with M6620 and in the absence of M6620 [1 year]
Parts A, B, B2: Objective tumor response (OR) as evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1 [1 year]
Part C2: Overall Response Rate in all participants in Part C2 [1 year]
Parts C1, C2, C3: Progression Free Survival (PFS) [1 year]
Parts C1, C2, C3: Response Duration (RD) [1 year]
Parts C1, C2, C3: Overall Survival (OS) [1 year]
Parts C1, C2, C3: Clinical benefit (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) of 6 months or greater) [1 year]
Parts C1, C2, C3: PK parameter estimates of M6620 including maximum concentrations (Cmax), area under the curve (AUC), apparent volume at steady state (Vss), clearance (CL) and terminal elimination half-life (t1/2) [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Disease status

Parts A and B/B2: Histologically or cytologically confirmed advanced solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or for whom regimens containing gemcitabine, cisplatin, etoposide, and/or irinotecan might be considered, and with measurable disease according to RECIST criteria
Part C1:

For Pre-screening:

Advanced (metastatic or locally-advanced unresectable and not eligible for definitive treatment, e.g., surgery/radiotherapy), histologically confirmed non-small cell lung cancer (NSCLC)
Available historical tumor specimen at the time of pre-screening or willing to provide a tumor biopsy (core) if the biopsy may be considered as part of standard clinical practice for the participant
Received or did not tolerate standard approved targeted therapy, if appropriate for tumor genotype

For Screening:

Measurable disease according to RECIST criteria

-Part C2:

Advanced (locally-advanced incurable or metastatic) histologically confirmed estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) negative breast cancer.
Adequate available historical tumor specimen or willing to provide a tumor biopsy (core) if the biopsy may be considered as part of standard clinical practice for the participant
Measurable disease according to RECIST criteria

-Part C3:

Advanced (locally-advanced incurable or metastatic) histologically confirmed SCLC that is platinum-resistant, defined as disease progression during initial treatment with a platinum-based regimen or progression within 90 days of completion of platinum therapy. Participants with platinum-resistant disease may receive a second-line non-platinum-based chemotherapy and subsequently be enrolled to this study. Participants who received and are resistant to a second-line platinum-based chemotherapy may also be enrolled into the study.
Adequate available historical tumor specimen or willing to provide a tumor biopsy (core) if the biopsy may be considered as part of standard clinical practice for the participant
Measurable disease according to RECIST criteria
WHO performance status of 0 or 1
Life expectancy of >=12 week
Hematological and biochemical indices within protocol specified ranges at screening.

Exclusion Criteria:

Radiotherapy (except for palliative reasons) endocrine therapy, immunotherapy, or chemotherapy during the previous 4 weeks (6 weeks for nitrosoureas and Mitomycin-C, and 4 weeks for investigational medicinal products) or less than 4 drug half-lives, whichever greater, before first dose of study drug.
Parts A, B and B2:
Greater than 6 cycles of prior treatment with cisplatin and/or carboplatin.

Part A/B: History of prior dose reductions or dose interruptions while receiving cisplatin or carboplatin due to toxicity from the platinum or intolerance to either agent.
Part B2: Prior exposure to irinotecan is permitted except for participants with a known hypersensitivity reaction to irinotecan.

Participants with a known history of Grade 4 thrombocytopenia or Grade 4 neutropenia while receiving prior therapy.
Part C1:
Any cytotoxic chemotherapy beyond 1 line of platinum-based chemotherapy. One additional line of non-platinum based therapy in the advanced setting

Pre-screening Only*: Participants may currently be receiving platinum-based chemotherapy in the advanced setting, or have completed 1 line of platinum-based chemotherapy and are currently receiving a second-line non-platinum-based therapy or maintenance therapy
There is no restriction on prior immunotherapy or targeted therapy unless combined together with a cytotoxic agent

Any prior gemcitabine for the treatment of NSCLC in any setting within 6 months
Participants who are known to be TP53 wild-type, unless they are determined to have ATM loss of expression during screening or pre-screening or until all the planned participants with TP53 mutation are enrolled as determined by the medical monitor
Participants with unknown TP53 mutational status will be enrolled until the group of approximately 10 participants without TP53 mutation or until all the planned participants with TP53 mutation are enrolled as determined by the medical monitor
Part C2:
Any prior platinum therapy in the adjuvant or neoadjuvant within 6 months of screening
Relapse within 3 months of completion of prior adjuvant or neoadjuvant chemotherapy
Any prior chemotherapy in the metastatic setting with the exception of either a taxane or an anthracycline in the first-line metastatic setting

(a) There is no restriction on prior immunotherapy or targeted therapy in the metastatic setting unless combined together with a cytotoxic agent

Participants with known BRCA1/BRCA2 germline mutations, either determined and documented prior to Screening, or determined during Screening. Participants with unknown BRCA1/BRCA2 status may be enrolled at discretion of the sponsor
Participants who are documented to be non-basaloid subtype using molecular profiling assay (e.g. PAM50 assay) prior to Screening
Participants with unknown BRCA1/BRCA2 or basaloid subtype status will be enrolled until the number of enrolled participant is approximately 40. If approximately 40 participants have been enrolled and a minimum of 30 participants who are basaloid positive and BRCA1/BRCA2 germline wild-type have not been enrolled, the basaloid subtype and BRCA status assay will be required at Screening to exclude participants who are basaloid negative or have BRCA1/BRCA2 germline mutations.
Part C3:
Prior platinum-sensitive participants , unless they progress on or within 90 days of completion of platinum-based regimen
There is no restriction on prior immunotherapy or targeted therapy in the metastatic setting unless combined together with a cytotoxic agent
During prior carboplatin therapy, requirement for dose reduction below AUC 5 mg.min/mL or discontinuation of carboplatin for toxicity or lack of tolerability.
Unresolved toxicity of Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater from previous anti-cancer therapy or radiotherapy
History of spinal cord compression or brain metastases, unless asymptomatic, treated, stable, and not requiring treatment with steroids for at least 4 weeks before first dose of study drug. Any history of leptomeningeal metastases.
Female participants who are already pregnant or lactating, or plan to become pregnant within 6 months of the last dose of study drug are excluded. Female participants of childbearing potential must adhere to contraception guidelines
Male participants with partners of child-bearing potential must agree to adhere to contraception guidelines. Men with pregnant or lactating partners or partners who plan to become pregnant during the study or within 6 months of the last dose of study drug are excluded
Serious cardiac or other co-morbid disease, as specified in the protocol
Prior bone marrow transplant or extensive radiotherapy to greater than 15% of bone marrow
Part C:
Current malignancies of other types, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin
Major surgery =<2 weeks before starting study drug, or incomplete recovery from a prior major surgical procedure.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic Arizona	Phoenix	Arizona	United States	85054
2	Sharp Memorial Hospital	San Diego	California	United States	92123
3		Stanford	California	United States
4	Rocky Mountain Cancer Centers, LLP	Denver	Colorado	United States	80218
5	Emory University	Atlanta	Georgia	United States	30322
6	Northwestern Center for Clinical Research	Chicago	Illinois	United States	60611
7	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02215
8	Breslin Cancer Center	Lansing	Michigan	United States	48910
9	University Of Minnesota Hospital	Minneapolis	Minnesota	United States	55455
10	Mayo Clinic - Rochester	Rochester	Minnesota	United States	55905
11	Washington University in St. Louis	Saint Louis	Missouri	United States	63110
12	Hackensack University Medical Center PARTNER	Hackensack	New Jersey	United States	07601
13	Long Island Jewish Medical Center - Monter Cancer Center	Lake Success	New York	United States	11042
14	University Hospitals Case Medical Center - Case Comprehensive Cancer Center at	Cleveland	Ohio	United States	44106
15	OSU - James Comprehensive Cancer Center - Division of Hematology	Columbus	Ohio	United States	43210
16	Greenville Health System	Greenville	South Carolina	United States	29605
17	Vanderbilt University Medical Center	Nashville	Tennessee	United States	37232
18	US Oncology - Texas Oncology-Midtown - Austin Midtown	Austin	Texas	United States	78705
19	Texas Oncology, P.A.	Dallas	Texas	United States	75231
20	University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner	Houston	Texas	United States	77030
21	Texas Oncology San Antonio Medical Cente	San Antonio	Texas	United States	78240
22	Virginia Cancer Specialists, PC	Fairfax	Virginia	United States	22031
23	Virginia Oncology Associates - Hampton	Norfolk	Virginia	United States	23502
24	Northwest Cancer Specialists , P.C.	Vancouver	Washington	United States	98684
25	Freeman Hospital - PARENT	Newcastle Upon Tyne	England	United Kingdom
26	Churchill Hospital - PARENT	Oxford	England	United Kingdom
27	Beatson West of Scotland Cancer Centre - Dept of Medical Oncology	Glasgow	Scotland	United Kingdom
28	Royal Marsden Hospital - Dept of Oncology	Sutton	Surrey	United Kingdom
29	Guy's Hospital - PARENT	London		United Kingdom
30	Sarah Cannon Research Institute UK	London		United Kingdom
31	The Christie - Dept of Oncology	Manchester		United Kingdom